IL151369A0 - USE OF TGF-beta ANTAGONISTS FOR PREPARATION OF A PHARMACEUTICAL COMPOSITION - Google Patents

USE OF TGF-beta ANTAGONISTS FOR PREPARATION OF A PHARMACEUTICAL COMPOSITION

Info

Publication number
IL151369A0
IL151369A0 IL15136901A IL15136901A IL151369A0 IL 151369 A0 IL151369 A0 IL 151369A0 IL 15136901 A IL15136901 A IL 15136901A IL 15136901 A IL15136901 A IL 15136901A IL 151369 A0 IL151369 A0 IL 151369A0
Authority
IL
Israel
Prior art keywords
tgf
preparation
pharmaceutical composition
beta antagonists
antagonists
Prior art date
Application number
IL15136901A
Other languages
English (en)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22691635&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL151369(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of IL151369A0 publication Critical patent/IL151369A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
IL15136901A 2000-03-09 2001-03-08 USE OF TGF-beta ANTAGONISTS FOR PREPARATION OF A PHARMACEUTICAL COMPOSITION IL151369A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18806000P 2000-03-09 2000-03-09
PCT/US2001/007473 WO2001066140A1 (en) 2000-03-09 2001-03-08 Use of tgf-beta antagonists to treat or to prevent loss of renal function

Publications (1)

Publication Number Publication Date
IL151369A0 true IL151369A0 (en) 2003-04-10

Family

ID=22691635

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15136901A IL151369A0 (en) 2000-03-09 2001-03-08 USE OF TGF-beta ANTAGONISTS FOR PREPARATION OF A PHARMACEUTICAL COMPOSITION
IL151369A IL151369A (en) 2000-03-09 2002-08-21 Use of tgf-beta antagonist for the preparation of pharmaceuticals

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL151369A IL151369A (en) 2000-03-09 2002-08-21 Use of tgf-beta antagonist for the preparation of pharmaceuticals

Country Status (10)

Country Link
EP (1) EP1263464B1 (da)
JP (1) JP2004502644A (da)
AU (1) AU2001272100A1 (da)
CA (1) CA2400628A1 (da)
DK (1) DK1263464T3 (da)
ES (1) ES2398039T3 (da)
HK (1) HK1047542A1 (da)
IL (2) IL151369A0 (da)
PT (1) PT1263464E (da)
WO (1) WO2001066140A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20030077247A1 (en) * 2001-09-20 2003-04-24 Schering Corporation Chemokines as adjuvants of immune response
EP1620128A1 (en) * 2003-04-30 2006-02-01 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
EP1843780A4 (en) * 2004-12-31 2010-03-17 Univ Queensland Methods of Treatment
AU2006244148A1 (en) * 2005-05-05 2006-11-16 Fibrogen, Inc. Cardiovascular disease therapies
DE602006021600D1 (de) * 2005-09-29 2011-06-09 Fibrogen Inc Verfahren zur senkung des blutdrucks
ITMI20060181A1 (it) * 2006-02-03 2007-08-04 Univ Padova Modulatori del tgf-b e loro uso
WO2007121233A1 (en) 2006-04-12 2007-10-25 Genzyme Corporation Methods of treating autoimmune diseases
WO2007137584A1 (en) * 2006-05-30 2007-12-06 Antibodyshop A/S Methods and devices for rapid assessment of severity of injury
EP2029625A2 (en) * 2006-06-05 2009-03-04 Novartis AG Use of tgf-beta antagonists in treatment of parathyroid-related disorders
DK2262520T3 (da) 2008-02-26 2017-08-07 Univ Cornell Sammensætninger til forebyggelse og behandling af nyreskader
WO2013068776A1 (en) * 2011-11-09 2013-05-16 Università Degli Studi Di Bari Combination of active ingredients for the treatment of acute kidney injury
ES2417679B1 (es) * 2011-12-09 2014-09-15 Servicio Andaluz De Salud Prevención y tratamiento de las lesiones renales asociadas a la litiasis renal de la vía urinaria.
EP2928562A4 (en) 2012-12-06 2016-06-22 Stealth Peptides Int Inc PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE
PT2971048T (pt) 2013-03-11 2019-02-06 Genzyme Corp Anticorpos anti-tgf-beta manipulados e fragmentos de ligação a antigénios
CA2921805C (en) 2013-08-22 2023-03-07 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
WO2015183995A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
EP3149035A4 (en) 2014-05-28 2018-05-16 Stealth BioTherapeutics Corp Therapeutic compositions including therapeutic small molecules and uses thereof
HK1256638A1 (zh) 2015-08-04 2019-09-27 Acceleron Pharma Inc. 用於治疗骨髓增生性病症的方法
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
AU2021234121A1 (en) * 2020-03-11 2022-09-29 Universitaet Bern Fetuin A for treatment of renal disorders
US20250034212A1 (en) 2021-09-30 2025-01-30 Peptidream Inc. Peptide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
WO1991004748A1 (en) 1989-09-29 1991-04-18 La Jolla Cancer Research Foundation INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX
ZA914750B (en) * 1990-06-20 1992-03-25 Bristol Myers Squibb Co Methods of modulating blood pressure using tgf-beta and antagonists thereof
EP0737071A1 (en) 1993-06-15 1996-10-16 Il- Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
JPH08333249A (ja) * 1995-06-07 1996-12-17 Ono Pharmaceut Co Ltd ＴＧＦ−β放出、活性化および合成抑制剤
AU3215597A (en) 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
NZ508317A (en) * 1998-05-22 2004-01-30 Boys Town Nat Res Hospital Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease

Also Published As

Publication number Publication date
CA2400628A1 (en) 2001-09-13
ES2398039T3 (es) 2013-03-13
IL151369A (en) 2013-08-29
JP2004502644A (ja) 2004-01-29
AU2001272100A1 (en) 2001-09-17
PT1263464E (pt) 2012-12-17
HK1047542A1 (zh) 2003-02-28
WO2001066140A1 (en) 2001-09-13
EP1263464A1 (en) 2002-12-11
EP1263464B1 (en) 2012-10-31
DK1263464T3 (da) 2013-01-28

Similar Documents

Publication Publication Date Title
IL151369A0 (en) USE OF TGF-beta ANTAGONISTS FOR PREPARATION OF A PHARMACEUTICAL COMPOSITION
EG24357A (en) New Pharmaceutical composition
IL152659A0 (en) Pharmaceutical composition
IL213240A (en) Pharmacy composition containing poly-fluorescein conjugate
GB0001621D0 (en) Pharmaceutical compositions
SI1524266T1 (sl) Farmacevtski sestavek
HUP0204555A3 (en) Pharmaceutical composition
AU6219601A (en) Pharmaceutical compositions
GB0009584D0 (en) Pharmaceutical compositions
AU8576801A (en) Pharmaceutical compositions
IL154238A0 (en) Pharmaceutical composition
HUP0301317A3 (en) Use of neuroprotective 7-beta-hydroxysteroids for preparation of pharmaceutical compositions
GB0008485D0 (en) Pharmaceutical compositions
HUP0200311A3 (en) Use of aroyl- or arylalkanoylpyridazines for preparation of pharmaceutical compositions
GB0005382D0 (en) Pharmaceutical composition
GB0014851D0 (en) Novel pharmaceutical formulation
GB0014892D0 (en) Novel pharmaceutical formulation
GB0014883D0 (en) Novel pharmaceutical formulation
GB0014947D0 (en) Novel pharmaceutical formulation
GB0014869D0 (en) Novel pharmaceutical formulation
HUP0103049A3 (en) Use of fluexetine for preparation of pharmaceutical compositions
GB0101094D0 (en) Pharmaceutical composition
GB0002691D0 (en) Pharmaceutical composition
EP1414417A4 (en) PHARMACEUTICAL FORMULATION
GB0019840D0 (en) Novel pharmaceutical formulation